$14.21
2.53% today
Nasdaq, Feb 05, 04:21 pm CET
ISIN
US15687V1098
Symbol
CERT

Certara Stock price

$13.86
+2.53 22.33% 1M
-1.05 7.04% 6M
+3.21 30.14% YTD
-2.38 14.66% 1Y
-11.99 46.38% 3Y
-24.22 63.60% 5Y
-24.22 63.60% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
-0.12 0.86%
ISIN
US15687V1098
Symbol
CERT

Key metrics

Market capitalization $2.23b
Enterprise Value $2.31b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 44.12
EV/Sales (TTM) EV/Sales 6.19
P/S ratio (TTM) P/S ratio 5.99
P/B ratio (TTM) P/B ratio 2.12
Revenue growth (TTM) Revenue growth 5.62%
Revenue (TTM) Revenue $372.80m
EBIT (operating result TTM) EBIT $1.36m
Free Cash Flow (TTM) Free Cash Flow $52.34m
Cash position $233.02m
EPS (TTM) EPS $-0.19
P/E forward negative
P/S forward 5.81
EV/Sales forward 6.02
Short interest 3.66%
Show more

Is Certara a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Certara Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Certara forecast:

5x Buy
42%
7x Hold
58%

Analyst Opinions

12 Analysts have issued a Certara forecast:

Buy
42%
Hold
58%

Financial data from Certara

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
373 373
6% 6%
100%
- Direct Costs 202 202
10% 10%
54%
171 171
0% 0%
46%
- Selling and Administrative Expenses 67 67
29% 29%
18%
- Research and Development Expense 37 37
14% 14%
10%
66 66
23% 23%
18%
- Depreciation and Amortization 65 65
19% 19%
17%
EBIT (Operating Income) EBIT 1.36 1.36
96% 96%
0%
Net Profit -31 -31
8% 8%
-8%

In millions USD.

Don't miss a Thing! We will send you all news about Certara directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Certara Stock News

Neutral
GlobeNewsWire
7 days ago
RADNOR, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2024 after the market close on Wednesday, February 26th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET.
Neutral
GlobeNewsWire
21 days ago
Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 million Confirms Adjusted EBITDA within Guidance Range of $120 million to $124 million
Neutral
GlobeNewsWire
about one month ago
RADNOR, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference.
More Certara News

Company Profile

Certara, Inc. engages in the provision of software and technology enables services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017 and is headquartered in Princeton, NJ.

Head office United States
CEO William Feehery
Employees 1,391
Founded 2008
Website www.certara.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today